UNIVEST FINANCIAL Corp Decreases Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

UNIVEST FINANCIAL Corp lessened its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 32,041 shares of the medical equipment provider’s stock after selling 535 shares during the quarter. UNIVEST FINANCIAL Corp’s holdings in Lantheus were worth $2,866,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in LNTH. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus during the third quarter worth about $25,000. Kestra Investment Management LLC acquired a new position in shares of Lantheus during the fourth quarter valued at approximately $27,000. UMB Bank n.a. lifted its position in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after acquiring an additional 134 shares in the last quarter. World Investment Advisors LLC acquired a new stake in shares of Lantheus in the third quarter worth approximately $60,000. Finally, Parkside Financial Bank & Trust increased its position in shares of Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after purchasing an additional 280 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $99.77 on Wednesday. The company has a market capitalization of $6.83 billion, a P/E ratio of 16.60 and a beta of 0.38. The company has a 50 day simple moving average of $92.91 and a 200-day simple moving average of $96.45. Lantheus Holdings, Inc. has a 1 year low of $57.92 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock valued at $6,110,806 over the last 90 days. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on LNTH. B. Riley lowered their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Truist Financial boosted their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group began coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. Finally, JMP Securities restated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.